Nibrozetone

N/A

Report date: 2024/01/08 10:43:10
NME

Base Information

Drug NameNibrozetone
Drug Alias NameABDNAZRRx-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitorsNuclear factor erythroid 2-related factor 2 inducersnitric oxide superagonist
TargetsNACHT, LRR and PYD domains-containing protein 3Nuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsBrain metastasesSolid tumoursStomatitis +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEpicentrx Inc
China Registration ClassN/A

Develop Information

Active CompaniesSciclone PharmaceuticalsEpicentrx IncSciclone Pharmaceutical (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsStomatitisSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsBrain metastasesSolid tumoursNeoplasm Metastasis +[9] 

Other Information

ATC CodeN/A
Related LinksN/A